Abstract
To verify the hypothesis that the non-conventional partial agonist (−)-CGP12177 binds at two β1-adrenoceptor sites, human β1-adrenoceptors, expressed in CHO cells, were labelled with (−)-[3H]-CGP12177. We compared the binding affinity and antagonist potency of 12 clinically used β-blockers against the cyclic AMP-enhancing effects of (−)-isoprenaline and (−)-CGP12177.
(−)-[3H]-CGP12177 bound to a high affinity site (H; KH=0.47 nM) and low affinity site (L); KL=235 nM). (−)-[3H]-CGP12177 dissociated from the β1-adrenoceptors with a fast component (koff=0.45 min−1), consistent with the L-site, and a slow component (koff=0.017–0.033 min−1), consistent with the H-site. (−)-Isoprenaline and (−)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with −logEC50M of 8.2 and 7.6. (−)-CGP12177 antagonised the effects of (−)-isoprenaline with a pKB of 9.9. The β-blockers antagonised the effects of (−)-isoprenaline more than the effects of (−)-CGP12177 with potency ratios: (−)-atenolol 1,000, (±)-metropolol 676, (−)-pindolol 631, (−)-timolol 589, (±)-carvedilol 204, (±)-oxprenolol 138, (±)-sotalol 132, (−)-propranolol 120, (±)-bisoprolol 95, (±)-alprenolol 81, (±)-nadolol 68 and (−)-bupranolol 56. In intact cells the binding constants of β-blockers, estimated from competition with 3–5 nM (−)-[3H]-CGP12177 (binding to the H-site), correlated with the corresponding affinities estimated from antagonism of the (−)-isoprenaline effects.
We conclude that (−)-[3H]-CGP12177 binds at two sites in the recombinant β1-adrenoceptor. (−)-CGP12177 is an antagonist of catecholamine effects through the H-site and a non-conventional partial agonist through the L-site. β-blockers are more potent antagonists through the H-site than the L-site.
Similar content being viewed by others
References
Baker JG, Hall IP, Hill SJ (2003) Agonist actions of β-blockers provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol 63:1312–1321
Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human heart. N Engl J Med 307:205–211
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S (1986) Beta-1 and beta-2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297–309
Gille E, Lemoine H, Ehle B, Kaumann AJ (1985) The affinity of (−)-propranolol for β1- and β2-adrenoceptors in human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation of (−)-noradrenaline and (−)-adrenaline. Naunyn-Schmiedeberg’s Arch Pharmacol 331:60–70
Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc Natl Acad Sci USA 89:5547–5551
Granneman JG (2001) The putative β4-adrenoceptor is a novel site of the β1-adrenergic receptor. Am J Physiol Endocrinol Metab 280:E199–E202
Hoffmann C, Leitz MR, Oberdorf-Maas S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human β-adrenergic receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg’s Arch Pharmacol 369:151–159
Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ (2003) Intrinsic sympathomimetic activity of (−)-pindolol mediated through a (−)-propranolol-resistant site of the β1-adrenoceptor in human atrium and recombinant receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 368:496–503
Kaumann AJ (1983) Cardiac β-adrenoceptors—experimental viewpoints. Z Kardiol 72:63–82
Kaumann AJ (1989) Is there a third heart β-adrenoceptor? Trends Pharmacol Sci 10:316–320
Kaumann AJ (1996) (−)-CGP12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br J Pharmacol 117:93–98
Kaumann AJ (2000) Gs protein-coupled receptors in human heart. In: Kenakin T, Angus JA (eds) The pharmacology of functional, biochemical, and recombinant receptor systems. Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 73–116
Kaumann AJ, Lobnig BM (1996) Mode of action of (−)-pindolol on feline and human myocardium. Br J Pharmacol 89:207–218
Kaumann AJ, Lynham JA (1997) Stimulation of cyclic AMP-dependent protein kinase in rat atria by (−)-CGP12177 through an atypical β-adrenoceptor. Br J Pharmacol 120:1187–1189
Kaumann AJ, Molenaar P (1996) Differences between the third cardiac β-adrenoceptor and the colonic β3-adrenoceptor in the rat. Br J Pharmacol 118:2085–2098
Kaumann AJ, Lemoine H, Morris T, Schwederski U (1982) An initial characterization of human heart β-adrenoceptors and their mediation of the positive inotropic effects of catecholamines. Naunyn-Schmiedeberg’s Arch Pharmacol 319:216–221
Kaumann AJ, Lynham JA, Sarsero D, Molenaar P (1997) The atypical cardiostimulant β-adrenoceptor is distinct from the β3-adrenoceptor and is coupled to a cyclic AMP-dependent pathway in rat and human myocardium. Br J Pharmacol 120:102P
Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, Giacobino JP (1998) (−)-CGP12177 causes cardiostimulation and binds to cardiac putative β4-adrenoceptors in both wild-type and β3-adrenoceptor knockout mice. Mol Pharmacol 53:670–675
Kaumann AK, Engelhardt S, Hein L, Molenaar P, Lohse M (2001) Abolition of (−)-CGP12177-evoked cardiostimulation in double β1-/β2-adrenoceptor knockout mice. Obligatory role of β1-adrenoceptors for putative β4-adrenoceptor pharmacology. Naunyn-Schmiedeberg’s Arch Pharmacol 363:87–93
Kompa AR, Summers RJ (1999) Desensitization and resensitization of β1- and the putative β4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure. Br J Pharmacol 128:1399–1406
Konkar AA, Zhai Y, Granneman JG (2000) β1-adrenergic receptors mediate β3-adrenergic-independent effects of CGP12177. Mol Pharmacol 57:252–258
Lemoine H, Schoennel H, Kaumann AJ (1988) Contribution of β1- and β2-adrenoceptors of human atrium and ventricle to the effects of noradrenaline and adrenaline as assessed with (−)-atenolol. Br J Pharmacol 95:55–66
Lowe MD, Grace AA, Vandenberg JI, KaumannA AJ (1998) Action potential shortening through putative β4-adrenoceptors in ferret ventricle: comparison with β1- and β2-adrenoceptor-mediated effects. Br J Pharmacol 124:1341–1344
Lowe MD, Grace AA, Kaumann AJ (1999) Blockade of putative β4- and β1-adrenoceptors by carvedilol in ferret myocardium. Naunyn-Schmiedeberg’s Arch Pharmacol 359:400–403
Lowe MD, Lynham JA, Grace A, Kaumann AJ (2002) Comparison of the affinity of β-blockers for two states of the β1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol 135:451–561
Mason A, Moore, DJ, Green SA, Liggett S (1999) A gain-of function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem 274:12670–12674
Pak MD, Fishman PH (1996) Anomalous behavior of CGP12177 on β1-adrenoceptors. J Recept Signal Transduct Res 16:1–23
Sarsero D, Molenaar P, Kaumann AJ (1998) Validity of (−)-[3H]-CGP12177 as a radioligand for the ‘putative β4-adrenoceptor’ in rat atrium. Br J Pharmacol 123:371–380
Sarsero D, Molenaar P, Kaumann AJ, Freestone NS (1999) Putative β4-adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: comparison with atrial receptors and relationship to (−)-[3H]-CGP12177 binding. Br J Pharmacol 128:1445–1460
Sarsero D, Russel FD, Lynham JA, Rabnott G, Yang I, Fong KM, Li L, Kaumann AJ, Molenaar P (2003) (−)-CGP12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the β1-adrenoceptor. Naunyn-Schmiedeberg’s Arch Pharmacol 367:10–21
Staehelin M, Simons P, Jaegghi K, Wigger (1983) CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258:3496–3502
Walter M, Lemoine H, Kaumann AJ (1984) Stimulant and blocking effects of optimal isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of β-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn-Schmiedeberg’s Arch Pharmacol 327:159–175
Wang T, Kaumann AJ, Brown MJ (1996) (−)-Timolol is a more potent antagonist of the positive inotropic effects of (−)-adrenaline than those of (−)-noradrenaline in human atrium. Br J Clin Pharmacol 42:217–223
Acknowledgement
We thank the British Heart Foundation for support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joseph, S.S., Lynham, J.A., Colledge, W.H. et al. Binding of (−)-[3H]-CGP12177 at two sites in recombinant human β1-adrenoceptors and interaction with β-blockers. Naunyn-Schmiedeberg's Arch Pharmacol 369, 525–532 (2004). https://doi.org/10.1007/s00210-004-0884-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-004-0884-y